Provided by Tiger Fintech (Singapore) Pte. Ltd.

Axsome Therapeutics

103.26
-0.3300-0.32%
Post-market: 101.35-1.9100-1.85%17:27 EDT
Volume:553.80K
Turnover:57.04M
Market Cap:5.15B
PE:-20.39
High:104.35
Open:102.37
Low:101.11
Close:103.59
Loading ...

Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire
·
04 Aug

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
04 Aug

Preview -- Barron's

Dow Jones
·
02 Aug

RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)

TIPRANKS
·
24 Jul

Mizuho Securities Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)

TIPRANKS
·
22 Jul

Cantor Fitzgerald Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

TIPRANKS
·
22 Jul

Piper Sandler Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)

TIPRANKS
·
22 Jul

Axsome Therapeutics: Promising Growth Driven by Robust Pipeline and Strategic Fit

TIPRANKS
·
22 Jul

Axsome Therapeutics’ Promising Pipeline and Growth Potential Justifies Buy Rating

TIPRANKS
·
22 Jul

Axsome Therapeutics Unveils Promising Phase 3 Trial Results for AXS-05 in Alzheimer's Agitation at R&D Day Event

Reuters
·
21 Jul

Axsome Therapeutics to Ring NASDAQ Opening Bell in Connection with Frontiers in Brain Health R&D Day Event

Reuters
·
21 Jul

Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Enliven Therapeutics (ELVN)

TIPRANKS
·
18 Jul

Axsome Therapeutics Inc. to Report Second Quarter 2025 Financial Results

Reuters
·
09 Jul

RBC Capital Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)

TIPRANKS
·
08 Jul

Axsome Therapeutics (AXSM) Initiated with a Buy at Oppenheimer

TIPRANKS
·
07 Jul

RBC Trims Price Target on Axsome Therapeutics to $184 From $186, Keeps Outperform Rating

MT Newswires Live
·
07 Jul

Axsome Therapeutics to Showcase Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City

Reuters
·
07 Jul

Axsome Therapeutics Coverage Assumed by Morgan Stanley at Overweight

Dow Jones
·
04 Jul

Axsome Therapeutics assumed with an Overweight at Morgan Stanley

TIPRANKS
·
03 Jul

Hunter R. Murdock, General Counsel, Reports Disposal of Axsome Therapeutics Inc. Common Shares

Reuters
·
24 Jun